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392Endovascular-ﬁrst approach is not associated with
worse amputation-free survival in appropriately
selected patients with critical limb ischemia
Karan Garg, MD, Patrick A. Kaszubski, BS, Rameen Moridzadeh, BS, Caron B. Rockman, MD,
Mark A. Adelman, MD, Thomas S. Maldonado, MD, Frank J. Veith, MD, and Firas F. Mussa, MS, MD,
New York, NY
Objective: Endovascular interventions for critical limb ischemia are associated with inferior limb salvage (LS) rates in most
randomized trials and large series. This study examined the long-term outcomes of selective use of endovascular-ﬁrst
(endo-ﬁrst) and open-ﬁrst strategies in 302 patients from March 2007 to December 2010.
Methods: Endo-ﬁrst was selected if (1) the patient had short (5-cm to 7-cm occlusions or stenoses in crural vessels); (2) the
disease in the superﬁcial femoral artery was limited to TransAtlantic Inter-Society Consensus II A, B, or C; and (3) no
impending limb loss. Endo-ﬁrst was performed in 187 (62%), open-ﬁrst in 105 (35%), and 10 (3%) had hybrid
procedures.
Results: The endo-ﬁrst group was older, with more diabetes and tissue loss. Bypass was used more to infrapopliteal targets
(70% vs 50%, P[ .031). The 5-year mortality was similar (open, 48%; endo, 42%; P[ .107). Secondary procedures (endo
or open) were more common after open-ﬁrst (open, 71 of 105 [68%] vs endo, 102 of 187 [55%]; P[ .029). Compared
with open-ﬁrst, the 5-year LS rate for endo-ﬁrst was 85% vs 83% (P[ .586), and amputation-free survival (AFS) was 45%
vs 50% (P[ .785). Predictors of death were age >75 years (hazard ratio [HR], 3.3; 95% conﬁdence interval [CI], 1.7-6.6;
P[ .0007), end-stage renal disease (ESRD) (HR, 3.4; 95% CI, 2.1-5.6; P < .0001), and prior stroke (HR, 1.6; 95% CI,
1.03-2.3; P [ .036). Predictors of limb loss were ESRD (HR, 2.5; 95% CI, 1.2-5.4; P [ .015) and below-the-knee
intervention (P [ .041). Predictors of worse AFS were older age (HR, 2.03; 95% CI, 1.13-3.7; P [ .018), ESRD
(HR, 3.2; 95% CI, 2.1-5.11; P < .0001), prior stroke (P [ .0054), and gangrene (P [ .024).
Conclusions: At 5 years, endo-ﬁrst and open-ﬁrst revascularization strategies had equivalent LS rates and AFS in patients
with critical limb ischemia when properly selected. A patient-centered approach with close surveillance improves long-
term outcomes for both open and endo approaches. (J Vasc Surg 2014;59:392-9.)Endovascular interventions for critical limb ischemia
(CLI) are viewed as an inferior long-term alternative to
open revascularization, especially when autologous saphe-
nous vein is available.1,2 Open bypass, however, can be
detrimental to those with reduced life expectancy from
severe comorbidities or with diminished quality of life.3
Furthermore, patients undergoing open revascularization
are at signiﬁcant risk for perioperative morbidity and
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://dx.doi.org/10.1016/j.jvs.2013.09.001The technological growth during the past few years has
led to wide adoption of complex endovascular approaches
(eg, infrapopliteal stenting, tibial atherectomy, retrograde
tibial access) by most interventionalists, including vascular
surgeons.5-9 Selecting the appropriate method of revascu-
larization should be based on the individual characteristics
of each patient (anatomy, comorbidities, extent of tissue
loss, expected beneﬁts in functional status), operator skill
level, and institutional algorithms.
We use an endovascular-ﬁrst (endo-ﬁrst) approach
based on patient-centered criteria. Patients with CLI
were offered revascularization based on lesion characteris-
tics and distribution as well as medical comorbidities,
with a preference for endo-ﬁrst interventions. The goal of
this study was to determine predictors and 5-year rates of
survival, limb salvage (LS), and amputations-free survival
(AFS) between endo-ﬁrst patients and open-ﬁrst patients
within our institution since the patient-centered approach
was incorporated.METHODS
The New York University School of Medicine Institu-
tional Review Board approved this study.
Study sample and data collection. From March 2007
to December 2010, endo-ﬁrst was selected if (1) the
patient had short (5-cm to 7-cm occlusions or stenoses in
Table I. Demographics, comorbidities, and Rutherford
classiﬁcation of the study population (N ¼ 292) by initial
open or endovascular (endo) procedure
Variable
Initial open
(n ¼ 105)
Initial endo
(n ¼ 187) P
Age, years
Mean 6 SD 74.1 6 11.5 75.5 6 11.6 .301a
Range 32-94 42-97
Sex
Male 59 (56) 85 (45) .078b
Female 46 (44) 102 (55)
Smoker 14 (13) 25 (13) .993b
Type 2 diabetes 54 (54) 134 (72) .0027b
Hypertension 77 (73) 146 (78) .360b
CAD 51 (49) 88 (47) .804b
ESRD 16 (15) 27 (14) .853b
CVA 29 (28) 61 (33) .375b
Previous CABG 27 (26) 37 (20) .240b
Rest pain 59 (56) 68 (36) .0010b
Ulcer 52 (50) 127 (68) .0020b
Gangrene 39 (27) 94 (50) .031b
Above-knee intervention 32 (30) 107 (57) <.0001b
CABG, Coronary artery bypass grafting; CAD, coronary artery disease;
CVA, cerebrovascular accident; ESRD, end-stage renal disease; SD, stan-
dard deviation.
Data are presented as number (%) unless otherwise indicated.
aDetermined by two-sample t-test.
bDetermined by c2 test.
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artery (SFA) was limited to TransAtlantic Inter-Society
Consensus (TASC) II A, B, or C; and (3) no impending
limb loss. Patients with signiﬁcant medical comorbidities
were also offered endo-ﬁrst, particularly those with TASC
II B and selected C lesions. Endo-ﬁrst was not used for
TASC II D lesions. Patients with long-segment occlusions
(ie, TASC II C and D lesions) with acceptable perioper-
ative risk were offered open revascularization.
Demographics, comorbidities, Rutherford classiﬁca-
tion, prior procedures, secondary open or endovascular
interventions, and the most distal target for revasculariza-
tion were analyzed. All patients met the criteria for chronic
CLI, deﬁned as rest pain, ulceration, or gangrene. Rest
pain was deﬁned as Rutherford class IV disease, tissue
loss as class V disease, and gangrene as class VI.
The procedures analyzed for primary and secondary
interventions were one or a combination of the following:
percutaneous transluminal angioplasty, with or without
atherectomy/stenting, infrainguinal bypass grafting, and
open bypass thrombectomy. If patients presented with
a prior procedure performed at another facility, it must
have occurred within the timeframe of the study for the
patient to be considered. Excluded from the study were
patients who underwent primary amputation, hybrid
procedures, or those with acute limb ischemia. Amputation
was deﬁned as a below-knee or above-knee amputation.
Study end points. The 5-year rates of survival, LS,
and AFS between the two groups were compared.
Technique for endovascular and open procedures.
Patients typically received 100 U/kg of heparin after
sheath placement. Clopidogrel bisulfate (300 mg) was
started in the recovery room and maintained (75 mg daily)
for 6 weeks. Lifelong enteric-coated acetylsalicylic acid
(81 mg) was also given.
The lesions were crossed using Glidewire (Terumo
Medical Corp, Somerset, NJ) and catheters without inten-
tionally using a subintimal approach. Routine nitinol-
based stenting was used in SFA occlusions >5 cm;
however, selective stenting was used for TASC II A
lesions. A prolonged inﬂation time, between 30 seconds
and 1 minute, was used for infrapopliteal lesions, with
selective off-label use of balloon-expandable, drug-eluting
coronary stenting for ﬂow-limiting dissections or signiﬁ-
cant recoil after angioplasty. For patients with SFA disease
or more proximal disease with concurrent infrapopliteal
disease, initial treatment was directed toward improving
inﬂow. Debulking (Foxhollow, Plymouth, Minn) was
used as an adjunctive procedure initially and became
more mainstream, especially in recent years in the infrapo-
pliteal distribution. Similarly, complex tibial interventions
(retrograde pedal access, buddy wire techniques with
multiple infrapopliteal vessel recanalization) were used
increasingly in later years.
Above-knee femoropopliteal bypasses were preferen-
tially performed using prosthetic grafts. All infrageniculate
bypasses were preferentially performed using autologous
veins, and all patients underwent vein mapping.All patients were followed up postoperatively, and at
3 months, 6 months, and every 6 months thereafter for
ankle-brachial index measurements, graft or stent veloci-
ties, and duplex imaging.
Statistical analysis. Descriptive statistics, such as the
calculation of means with standard deviations and percent-
ages, were used to summarize the study population. The
percentage of patients with each type of procedure
(including the various combinations of initial and
secondary procedures) was calculated. Patient characteris-
tics, including demographics, comorbidities, and Ruther-
ford classiﬁcation, were compared between patients who
had an initial open procedure and patients who had an
initial endovascular procedure. The rate of each outcome
(LS, amputation, AFS, and death) was calculated for the
study population. The association between procedure
type and LS was analyzed using c2 tests and multiple
logistic regression analysis. For amputation, AFS, and death,
Kaplan-Meier with log-rank tests and Cox regression
were used to account for differential length of follow-up.
Similar analyses were conducted to determine if demo-
graphics, comorbidities, or Rutherford classiﬁcation, alone
or combined, were associated with outcomes. All tests were
two-sided, and values of P< .05 were considered signiﬁcant.
SAS 9.3 software (SAS Institute, Cary, NC) was used for
statistical analysis.
RESULTS
Demographics. During the study period, 302 patients
underwent infrainguinal revascularization and were included
Fig 1. Kaplan-Meier analysis shows time until amputation in patients after an initial open procedure (n ¼ 102)
compared with patients after an initial endovascular (endo) procedure (n ¼ 170). CI, Conﬁdence interval.
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ﬁrst, and 105 (35%) had initial open procedures. Ten patients
(3%) had combined (hybrid) procedures and were excluded
from our analysis. Patients in the endo-ﬁrst group were
more likely to be diabetic (77% vs 54%; P ¼ .0041) and
to present with ulcer (70% vs 50%; P ¼ .011) or
gangrene (50% vs 27%; P ¼ .031). Patients in the initial
open group were more likely to present with rest pain
(56% vs 36%; P ¼ .001). Patients in the endo-ﬁrst group
were more likely to receive above-knee interventions
(57% vs 30%; P # .0001). No difference was found
between two groups with respect to age, sex, active
smoking status, hypertension, coronary artery disease,
end-stage renal disease (ESRD), cerebrovascular accident
(CVA), and previous coronary artery bypass grafting
(Table I). No patients died in the perioperative period.
LS. At 5 years, no difference was found in LS between
endo-ﬁrst (85%; 95% conﬁdence interval [CI], 79%-92%)
and initial open (83%; 95% CI, 75%-91%; Fig 1). In the
unadjusted Cox regression model, procedure type was not
associated with LS (P ¼ .415). After controlling for ESRD
and Rutherford classiﬁcation, procedure type was still not
associated with LS (P ¼ .586).
Survival. At 5 years, no difference was found in
survival rates between endo-ﬁrst (58%; 95% CI, 49%-
67%) and initial open (52%; 95% CI, 40%-64%; Fig 2). In
the unadjusted Cox regression model, procedure type wasnot associated with survival (P ¼ .508). After controlling
for age, ESRD, CVA, and Rutherford classiﬁcation, endo-
ﬁrst demonstrated a trend toward improved survival
beneﬁt; however, this ﬁnding was not statistically signiﬁ-
cant (odds ratio, 1.40; 95% CI, 0.93-2.09; P ¼ .107).
AFS. At 5 years, no difference was found between
endo-ﬁrst (55%; 95% CI, 44%-66%) and initial open
(50%; 95% CI, 39%-62%; Fig 3). In the unadjusted Cox
regression model, procedure type was not associated with
AFS (P ¼ .548). After controlling for age, ESRD, CVA,
and Rutherford classiﬁcation, procedure type was still not
statistically signiﬁcant (P ¼ .785).
Independent predictors of survival, LS, and AFS.
ESRD was a predictor of worse LS (odds ratio, 2.5; P ¼
.028), survival (hazard ratio [HR], 3.5; P < .0001), and
AFS (HR, 3.26; P < .0001). Age predicted worse survival
in those aged 75 to 84 years (HR, 3.30; P ¼ .0007) and
$85 years (HR, 5.34; P < .0001). Similarly, ages 75 to
84 (HR, 2.03; P ¼ .018) and $85 (HR, 4.35; P <
.0001) predicted worse AFS. Prior stroke predicted worse
survival (HR, 1.55; P ¼ .036). Patients undergoing
above-knee interventions were more likely to have LS
(HR, 2.17; P ¼ .041; Tables II-VI).
DISCUSSION
By individualizing open revascularization and endo-
vascular therapy based on patient and lesion characteristics,
Fig 2. Kaplan-Meier analysis shows time until death in patients after an initial open procedure (n ¼ 95) compared with
patients after an initial endovascular (endo) procedure (n ¼ 168). CI, Conﬁdence interval.
Fig 3. Kaplan-Meier analysis shows time with amputation-free survival (AFS) in patients after an initial open procedure
(n ¼ 102) compared with patients after an initial endovascular (endo) procedure (n ¼ 170). CI, Conﬁdence interval.
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Table II. Bivariate association of demographics, comorbidities, Rutherford classiﬁcation, and procedure type with
outcomes limited to those with an initial open or initial endovascular (endo) procedure (N ¼ 292a)
Variable No.
LS Amputation Death AFS
% P 1-year, % P 1-year, % 3-year, % P 1-year, % 3-year, % P
Age, years
<65 52 83 .408b 17 .417d 17 24 <.0001d 84 79 <.0001d
65-74 75 85 13 14 22 86 79
75-84 105 91 9 27 43 74 68
$85 60 87 8 50 63 51 42
Sex
Male 144 85 .333b 14 .164d 29 38 .918d 72 67 .740d
Female 148 89 8 24 38 77 69
Smoker
Yes 39 92 .440c 3 .387d 25 33 .666d 75 67 .565d
No 253 87 13 26 38 75 68
Type 2 diabetes
Yes 191 86 .506b 12 .554d 27 38 .810d 75 69 .967d
No 101 89 10 26 38 75 66
Hypertension
Yes 223 88 .602b 10 .433d 27 39 .379d 74 67 .530d
No 69 86 15 25 34 77 70
CAD
Yes 139 88 .829b 11 .777d 28 42 .340d 74 67 .799d
No 153 87 12 25 34 76 69
ESRD
Yes 43 77 .024b 23 .0040d 49 69 .0001d 55 45 <.0001d
No 249 89 10 22 33 78 72
CVA
Yes 90 88 .878b 12 .743d 39 53 .0015d 63 55 .0054d
No 202 87 11 21 31 80 74
Previous CABG
Yes 64 84 .422b 11 .339d 25 35 .676d 77 70 .530d
No 228 88 12 27 39 74 67
Rest pain
Yes 127 86 .499b 14 .369d 27 35 .598d 74 69 .640d
No 165 88 9 26 40 75 68
Ulcer
Yes 179 88 .806b 10 .932d 26 39 .641d 74 67 .440d
No 113 87 14 26 35 75 70
Gangrene
Yes 133 84 .143b 15 .094d 33 44 .068d 69 62 .024d
No 159 90 9 21 33 79 73
Above-knee intervention
Yes 139 91 .048b 7 .017d 30 41 .433d 70 64 .674d
No 153 84 16 22 35 79 72
AFS, Amputation-free survival; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVA, cerebrovascular accident; ESRD, end-stage renal
disease; LS, limb salvage.
aOverall n ¼ 272 for the analysis of amputation, overall n ¼ 263 for the mortality analysis, and overall n ¼ 272 for the AFS analysis.
bDetermined by c2 test.
cDetermined by the Fisher exact test.
dDetermined by log-rank test.
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treatment groups at 5 years for overall survival, LS, and
AFS. The two patient groups were different at baseline,
with a higher prevalence of diabetes and above-knee inter-
ventions in the endo-ﬁrst cohort. Indications for interven-
tion differed, with a higher prevalence of rest pain in the
open-ﬁrst cohort, and a higher prevalence of ulcer or
gangrene in the endo-ﬁrst group. An endo-ﬁrst approach
was preferentially used to treat short-segment lesions in
the femoropopliteal segments and crural vessels. At 5 years,the primary end points were similar between the two
patient cohorts. A comparison of patients undergoing
endo-ﬁrst vs an open-ﬁrst approach found overall survival
was 58% vs 52%, respectively; LS was 85% vs 82%, respec-
tively; and AFS was 55% vs 50%, respectively. ESRD was
a predictor of limb loss and death. Older patients had
a lower AFS, whereas above-knee interventions were
associated with a higher LS rate. The two groups were
dissimilar owing to our patient-centered approach, making
it unfair to draw outright comparisons; however, our
Table III. Independent predictors of limb salvage (LS)
Predictor OR (95% CI) P
ESRD
Yes 0.40 (0.18-0.90) .028
No Reference
CI, Conﬁdence interval; ESRD, end-stage renal disease; OR, odds ratio.
Table IV. Independent predictors of time until
amputation
Predictor HR (95% CI) P
ESRD
Yes 2.54 (1.20-5.39) .015
No Reference
Above-knee intervention
Yes 0.46 (0.22-0.97) .041
No Reference
CI, Conﬁdence interval; ESRD, end-stage renal disease; HR, hazard ratio.
Table V. Independent predictors of time until death
Predictor HR (95% CI) P
Age, years
<65 Reference
65-74 1.30 (0.60-2.83) .506
75-84 3.30 (1.65-6.61) .0007
$85 5.34 (2.60-10.99) <.0001
ESRD
Yes 3.43 (2.09-5.64) <.0001
No Reference
CVA
Yes 1.55 (1.03-2.32) .036
No Reference
CI, Conﬁdence interval; CVA, cerebrovascular accident; ESRD, end-stage
renal disease; HR, hazard ratio.
Table VI. Independent predictors of time with
amputation-free survival (AFS)
Predictor HR (95% CI) P
Age, years
<65 Reference
65-74 1.18 (0.63-2.24) .602
75-84 2.03 (1.13-3.66) .018
85þ 4.35 (2.37-7.96) <.0001
ESRD
Yes 3.26 (2.08-5.11) <.0001
No Reference
CI, Conﬁdence interval; ESRD, end-stage renal disease; HR, hazard ratio.
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the literature.
Dosluoglu et al10 undertook a methodical approach
similar to ours. They reported 514 limbs in 433 patients
in Veterans Affairs hospital spanning 8 years. At 5 years,
the LS rate was 78% in both cohorts, with no difference
in AFS or overall survival. Although there was no difference
in 5-year primary patency, the assisted primary patency and
secondary patency were improved in the endovascular
group compared with the open group: 70% vs 59% (P ¼
.037) and 73% vs 64% (P ¼ .022), respectively. The
authors concluded that the endovascular group consisted
of medically higher-risk patients whereas the bypass group
had complex multilevel disease that required more infrapo-
pliteal interventions. Overall, by individualizing treatment
based on patient characteristics, the authors were able to
achieve comparable outcomes with acceptable LS.
Kudo et al9 reported a 12-year experience with CLI.
They used an open-ﬁrst and endo-ﬁrst in a complementary
fashion, guided by a patient-centered approach. Despite
a signiﬁcant shift toward endovascular interventions, they
noted no difference in long-term outcomes. Similarly,
Soga et al11 reported their outcomes from a retrospective
registry consisting of 460 limbs with CLI with de novo
infrainguinal lesions. Patients were grouped by those
undergoing bypass surgery or endovascular therapy. At
3 years, they reported no difference in AFS, LS, or overall
survival.11
Conrad et al12 identiﬁed 447 limbs in 409 patients who
underwent interventions for CLI, of which 16% were
limited to crural vessels, 38% had multilevel interventions,
and the SFA was treated in 56% of limbs. Their mean
follow-up was 28 months (range, 8-83 months). At 5 years,
they reported a primary patency of 31%, assisted patency of
75%, overall survival of 39%, and LS of 74%.12 On multivar-
iate analysis, female gender, poor runoff, and dialysisdependence were associated with increased risk of limb
loss. They conclude that despite a low primary patency,
excellent LS rates can be achieved with close follow-up
and secondary interventions, lending further support for
an endo-ﬁrst approach in appropriately selected patients.
An important predictor of treatment outcomes is lesion
characteristics. Using TASC II, Giles et al13 justiﬁed an
endo-ﬁrst approach for CLI with close follow-up. They re-
ported an excellent LS rate of 84% at 3 years, with poorer
technical success in treating TASC D lesions of 75% vs
100% for TASC A, B, or C (P < .001).13 In a follow-up
study from the same institution, unsuitability for bypass
and TASC D lesions were associated with increased risk
of amputation, whereas TASC A, B, and C lesions can
safely be treated using an endo-ﬁrst approach.14
Although the aforementioned single-institution studies
report promising results, the only randomized study to
date, the Bypass vs Angioplasty in Severe Ischaemia of
the Leg (BASIL) trial, found that at 2 years, the primary
outcomes of death and amputation between the two
treatment groups were comparable.15 However, among
patients surviving >2 years, those undergoing a bypass
had superior overall survival and a trend toward improved
AFS.16 The AFS rate was >50% in both groups at the study
end point. Outcomes from the BASIL trial suggest the
superiority of open surgery for CLI and have inﬂuenced
contemporary guidelines in approaching CLI; however,
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this group of patients.
Comorbid conditions have a signiﬁcant affect on LS
and mortality. Our ﬁndings corroborate other studies
that have demonstrated poor outcomes in patients with
ESRD.17-20 In addition, the level of intervention affects
LS rates, with signiﬁcantly higher limb loss associated
with infrapopliteal interventions than with above-knee
interventions.21,22
Our study has the limitations associated with being
a single-institution retrospective study. The two groups
were different by design, with differences in comorbidities
as well as in characteristics, thus making it difﬁcult to
directly compare the two groups. A well-designed random-
ized study would best address the efﬁcacy of an endovascu-
lar or open approach to treating CLI, but the difﬁculty
remains in the design of such a trial. Patients with CLI
have signiﬁcant comorbidities and variable distribution of
disease, making randomization of two similar cohorts an
arduous if not impossible task. Furthermore, as suggested
by recent studies, there may be merit in individualizing
treatment strategies rather than in using a single approach.
CONCLUSIONS
CLI arises in a sick cohort of patients with multiple
medical comorbidities who, despite adequate therapy,
remain at a high risk for limb loss and poor overall
survival.23,24 Deciding the appropriate treatment approach
in such a population is critical to minimizing morbidity
while optimizing outcomes. Although endovascular inter-
ventions have gained widespread acceptance in treating
CLI, we believe they have been used indiscriminately at
times. This may have led to poorer outcomes when
compared head-to-head with open bypass, especially in
case-cohort studies. Our experience adds to the growing
body of literature in support of an endo-ﬁrst approach in
appropriately selected patients.AUTHOR CONTRIBUTIONS
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